Related Experiment Video
Updated: Aug 20, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
[Atherosclerosis and vascular calcification in hemodialysis patients]
Naohisa Hirasaka1, Xiang-Ming Liang, Masatoshi Mune
1Department of Internal Medicine III, Wakayama Medical University.
Insights
Cardiovascular disease is a major concern for hemodialysis patients, with higher mortality rates due to atherosclerosis and vascular calcification. Oxidative stress and hyperphosphatemia are key contributors, but Vitamin E and phosphate control may offer protection.
Area of Science:
- Nephrology and Cardiovascular Medicine
- Biochemistry and Oxidative Stress
Context:
- Cardiovascular disease (CVD) is the leading cause of mortality in patients undergoing hemodialysis, with rates five to twenty times higher than the general population.
- Atherosclerosis and vascular calcification are prevalent complications, driven by traditional risk factors (e.g., abnormal lipid metabolism) and uremia-specific factors (e.g., oxidative stress, hyperphosphatemia).
Purpose:
- To elucidate the mechanisms linking oxidative stress and hyperphosphatemia to accelerated atherosclerosis and vascular calcification in hemodialysis patients.
- To highlight the role of Matrix Gla Protein (MGP) in vascular calcification and the potential protective effects of Vitamin E and phosphate management.
Summary:
- Oxidative stress in hemodialysis patients involves increased oxidant production and decreased antioxidant levels (Vitamins C and E), leading to modified LDL and promoting atherosclerosis.
- Both oxidative stress and hyperphosphatemia contribute to vascular calcification, characterized by mineral deposition in the tunica media.
- MGP knockout mice exhibit significant calcification, indicating MGP's inhibitory role. Vitamin E demonstrates protective effects against atherosclerosis and vascular calcification.
Impact:
- Understanding these pathways is crucial for developing targeted interventions to reduce cardiovascular mortality in hemodialysis patients.
- Therapeutic strategies focusing on antioxidant supplementation (Vitamin E) and strict hyperphosphatemia control are essential for mitigating vascular complications.
Abstract:
Cardiovascular disease is the largest cause of mortality in hemodialysis patients. Cardiovascular mortality is fivefold to twentyfold higher in hemodialysis patients than in the general population. Atherosclerosis and vascular calcification are the characteristic complications in hemodialysis patients. Hemodialysis patients have traditional risk factors such as abnormal lipid metabolism and uremia-related risk factors such as oxidative stress and hyperphosphatemia. Oxidative stress takes place by increased production of oxidants by leukocytes and antioxidant loss of vitamin C and E. Oxidatively modified LDL exist in the circulation by excess of oxidative stress in hemodialysis patients. Oxidative stress is a major contributor to accelerated development atherosclerosis. Oxidative stress and hyperphosphatemia also influence vascular calcification. The pattern of vascular calcification in hemodialysis patient is characterized by mineral deposition in the tunica media. It is reported that the obvious calcification in aorta and artery of the MGP knockout mouse is recognized. It is indicated that MGP has the inhibitory effect of the calcification of vessel wall. Vitamin E protects atherosclerosis and vascular calcification in hemodialysis patients. It is also important to control hyperphosphatemia for vascular calcification.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Chronic Kidney Disease II: Clinical Manifestations
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Hemodialysis III: Nursing Management

